These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23326337)

  • 41. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
    Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ;
    Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.
    Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R
    Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Steroid therapy and cardiac function in Duchenne muscular dystrophy.
    Markham LW; Spicer RL; Khoury PR; Wong BL; Mathews KD; Cripe LH
    Pediatr Cardiol; 2005; 26(6):768-71. PubMed ID: 15990951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.
    Connolly AM; Schierbecker J; Renna R; Florence J
    Neuromuscul Disord; 2002 Dec; 12(10):917-25. PubMed ID: 12467746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
    Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J;
    PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy.
    Parreira SL; Resende MB; Della Corte Peduto M; Marie SK; Carvalho MS; Reed UC
    Arq Neuropsiquiatr; 2007 Jun; 65(2A):245-50. PubMed ID: 17607422
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data.
    Pane M; Coratti G; Brogna C; Mazzone ES; Mayhew A; Fanelli L; Messina S; D'Amico A; Catteruccia M; Scutifero M; Frosini S; Lanzillotta V; Colia G; Cavallaro F; Rolle E; De Sanctis R; Forcina N; Petillo R; Barp A; Gardani A; Pini A; Monaco G; D'Angelo MG; Zanin R; Vita GL; Bruno C; Mongini T; Ricci F; Pegoraro E; Bello L; Berardinelli A; Battini R; Sansone V; Albamonte E; Baranello G; Bertini E; Politano L; Sormani MP; Mercuri E
    PLoS One; 2018; 13(6):e0199223. PubMed ID: 29924848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy.
    De Sanctis R; Pane M; Sivo S; Ricotti V; Baranello G; Frosini S; Mazzone E; Bianco F; Fanelli L; Main M; Corlatti A; D'Amico A; Colia G; Scalise R; Palermo C; Alfonsi C; Tritto G; Romeo DM; Graziano A; Battini R; Morandi L; Bertini E; Muntoni F; Mercuri E
    Neuromuscul Disord; 2015 Jan; 25(1):14-8. PubMed ID: 25454732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Atkinson L; Elfring GL; Reha A; Miller LL
    Muscle Nerve; 2010 Dec; 42(6):966-74. PubMed ID: 21038378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
    Beenakker EA; Fock JM; Van Tol MJ; Maurits NM; Koopman HM; Brouwer OF; Van der Hoeven JH
    Arch Neurol; 2005 Jan; 62(1):128-32. PubMed ID: 15642859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy.
    Kempen JC; Harlaar J; van der Kooi AJ; de Groot IJ; van den Bergen JC; Niks EH; Verschuuren JJ; Brehm MA
    Neuromuscul Disord; 2014 Mar; 24(3):216-21. PubMed ID: 24365209
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    Muntoni F; Domingos J; Manzur AY; Mayhew A; Guglieri M; ; Sajeev G; Signorovitch J; Ward SJ
    PLoS One; 2019; 14(9):e0221097. PubMed ID: 31479456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial.
    Seferian AM; Moraux A; Annoussamy M; Canal A; Decostre V; Diebate O; Le Moing AG; Gidaro T; Deconinck N; Van Parys F; Vereecke W; Wittevrongel S; Mayer M; Maincent K; Desguerre I; Thémar-Noël C; Cuisset JM; Tiffreau V; Denis S; Jousten V; Quijano-Roy S; Voit T; Hogrel JY; Servais L
    PLoS One; 2015; 10(2):e0113999. PubMed ID: 25643053
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study.
    Mazzone ES; Coratti G; Sormani MP; Messina S; Pane M; D'Amico A; Colia G; Fanelli L; Berardinelli A; Gardani A; Lanzillotta V; D'Ambrosio P; Petillo R; Cavallaro F; Frosini S; Bello L; Bonfiglio S; De Sanctis R; Rolle E; Forcina N; Magri F; Vita G; Palermo C; Donati MA; Procopio E; Arnoldi MT; Baranello G; Mongini T; Pini A; Battini R; Pegoraro E; Torrente Y; Previtali SC; Bruno C; Politano L; Comi GP; D'Angelo MG; Bertini E; Mercuri E
    PLoS One; 2016; 11(3):e0151445. PubMed ID: 26982196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids.
    Goemans N; Tulinius M; Kroksmark AK; Wilson R; van den Hauwe M; Campion G
    Neuromuscul Disord; 2017 Mar; 27(3):203-213. PubMed ID: 28169120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
    Victor RG; Sweeney HL; Finkel R; McDonald CM; Byrne B; Eagle M; Goemans N; Vandenborne K; Dubrovsky AL; Topaloglu H; Miceli MC; Furlong P; Landry J; Elashoff R; Cox D;
    Neurology; 2017 Oct; 89(17):1811-1820. PubMed ID: 28972192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retrospective Analysis of Fractures and Factors Causing Ambulation Loss After Lower Limb Fractures in Duchenne Muscular Dystrophy.
    Yildiz S; Glanzman AM; Estilow T; Flickinger J; Brandsema JF; Tennekoon G; Banwell BL; Yum S
    Am J Phys Med Rehabil; 2020 Sep; 99(9):789-794. PubMed ID: 32195737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
    Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.